Markets

Novartis: In the Pipeline

This major pharmaceutical company may be the best positioned among its peers.

Novartis AG, the giant, Swiss-based drugmaker, sells at about $57 a share -- just $5 more than it sold for in 1999. But the stock's tepid appreciation seems likely to accelerate over the next several years.

Novartis on Monday reported that first-quarter earnings rose 32% from the same period a year ago, to 83 cents per share. Part of the increase was attributed to lower marketing costs, but most was because of a 13% increase in sales, to $8.3 billion. The stock, however, barely budged because analysts -- while surprised by the robust earnings number -- had, on average, expected revenues of $8.5 billion.

But Novartis may well be the best positioned of the major pharmaceutical companies. It has four blockbuster drugs -- drugs with annual sales over $1 billion. They are leukemia drug Gleevec; Lotrel and Diovan for hypertension; and Zometa, another cancer drug. Sales of all four are still growing at double-digit annual rates.

The pipeline? "That's where it gets really exciting," says Trevor Polischuk, an analyst with Orbimed Advisors, which manages Eaton Vance Worldwide Health Sciences fund. Novartis is the largest holding in the fund at more than 7% of assets. Novartis just filed with the Food and Drug Administration for approval of two new drugs, one for hypertension and one for diabetes. "They'll be first-in-class drugs," says Polischuk. "They're not 'me-too' drugs." In addition, he says, Novartis boasts "a whole host" of other promising drugs in its pipeline.

What's more, Novartis faces few expiring patents in the near future, a problem that bedevils many other big pharmaceutical companies. Only one of its key drugs will lose patent protection by the end of the decade. Novartis must contend with some of the same pressures that other drug companies face, however -- most important, pressure by governments around the world to stem rapidly rising drug costs.

Chief executive Dan Vasella has done a fine job fostering the right atmosphere to keep research scientists developing new drugs. He worries some on Wall Street, though, because he's acquisitive. But Novartis's most recent purchase, biotech company Chiron, looks promising. "Novartis has deep pockets, tons of cash flow and a great balance sheet," Polischuk says. Indeed, debt is just 4% of capital, and the firm has $11 billion in cash and securities.

The stock (symbol NVS) sells at 17 times Polischuk's 2006 earnings estimate of $3.32 per share. That's about the same price-earnings ratio as most of Novartis's rivals. But Polischuk figures that Novartis's earnings will grow 17% per year through 2009 -- much more than its competitors. "On a price-earnings-to-growth basis, Novartis is the cheapest of all the big pharma companies" he says.

--Steven Goldberg

Most Popular

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer
Coronavirus and Your Money

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer

The IRS has an online tool that lets you track the status of your second stimulus check.
January 18, 2021
When Could We Get a Third Stimulus Check?
Coronavirus and Your Money

When Could We Get a Third Stimulus Check?

President Biden and others in Congress are pushing for a third-round of stimulus checks, but it might be a while before we get them.
January 20, 2021
6 Reasons Why Your Second Stimulus Check Might Be Delayed
Coronavirus and Your Money

6 Reasons Why Your Second Stimulus Check Might Be Delayed

The IRS started delivering second-round payments in December. If you're still waiting for your money, here's why your second stimulus check could be l…
January 18, 2021

Recommended

Kiplinger’s Mutual Fund Rankings, 2021
Kip 25

Kiplinger’s Mutual Fund Rankings, 2021

In a volatile year, the best portfolios had plenty of opportunity to shine.
January 23, 2021
SEC Dings Robinhood for Trading Charges
Business Costs & Regulation

SEC Dings Robinhood for Trading Charges

The complaints are a reminder to investors who pay low or no commissions to investigate more-opaque costs.
January 21, 2021
The Best and Worst Presidents (According to the Stock Market)
Markets

The Best and Worst Presidents (According to the Stock Market)

Which American presidents oversaw the best stock market performances? Just for grins, let's see what a 'stock market Mount Rushmore' might look like.
January 19, 2021
Is the Stock Market Open on Inauguration Day 2021?
Markets

Is the Stock Market Open on Inauguration Day 2021?

The federal government will enjoy an off day on Inauguration Day, but the stock and bond markets alike will conduct business as usual.
January 19, 2021